Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 1111 AL 1125

Transcranial blood-brain barrier opening in Alzheimer's disease patients using a portable focused ultrasound system with real-time 2-D cavitation mapping

Bae S, Liu K, Pouliopoulos AN, Ji R, Jiménez-Gambín S, Yousefian O, Kline-Schoder AR, Batts AJ, Tsitsos FN, Kokossis D, Mintz A, Honig LS, Konofagou EE.

Theranostics. 2024 Jul 22;14(11):4519-4535. doi: 10.7150/thno.94206. eCollection 2024.

The informatics of ADNI

Toga AW, Neu S, Sheehan ST, Crawford K; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2024 Oct;20(10):7320-7330. doi: 10.1002/alz.14099. Epub 2024 Aug 14.

Contributions of the ADNI Biostatistics Core

Beckett LA, Saito N, Donohue MC, Harvey DJ; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2024 Oct;20(10):7331-7339. doi: 10.1002/alz.14159. Epub 2024 Aug 14.

CT1812 biomarker signature from a meta-analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease

Lizama BN, Williams C, North HA, Pandey K, Duong D, Di Caro V, Mecca AP, Blennow K, Zetterberg H, Levey AI, Grundman M, van Dyck CH, Caggiano AO, Seyfried NT, Hamby ME.

Alzheimers Dement. 2024 Oct;20(10):6860-6880. doi: 10.1002/alz.14152. Epub 2024 Aug 21.

Updates in Alzheimer's disease: from basic research to diagnosis and therapies

Liu E, Zhang Y, Wang JZ.

Transl Neurodegener. 2024 Sep 4;13(1):45. doi: 10.1186/s40035-024-00432-x.

Breaking Barriers in Alzheimer's Disease: the Role of Advanced Drug Delivery Systems

Shekho D, Mishra R, Kamal R, Bhatia R, Awasthi A.

AAPS PharmSciTech. 2024 Sep 5;25(7):207. doi: 10.1208/s12249-024-02923-6.

Pathways to personalized medicine-Embracing heterogeneity for progress in clinical therapeutics research in Alzheimer's disease

Arnold SE, Hyman BT, Betensky RA, Dodge HH.

Alzheimers Dement. 2024 Oct;20(10):7384-7394. doi: 10.1002/alz.14063. Epub 2024 Sep 6.

Fluid biomarkers in the context of amyloid-targeting disease-modifying treatments in Alzheimer's disease

Hu Y, Cho M, Sachdev P, Dage J, Hendrix S, Hansson O, Bateman RJ, Hampel H.

Med. 2024 Oct 11;5(10):1206-1226. doi: 10.1016/j.medj.2024.08.004. Epub 2024 Sep 9.

Association between blood-based protein biomarkers and brain MRI in the Alzheimer's disease continuum: a systematic review

Mitolo M, Lombardi G, Manca R, Nacmias B, Venneri A.

J Neurol. 2024 Nov;271(11):7120-7140. doi: 10.1007/s00415-024-12674-w. Epub 2024 Sep 12.

Japanese Subgroup Analyses from EMERGE and ENGAGE, Phase 3 Clinical Trials of Aducanumab in Patients with Early Alzheimer's Disease

Toda Y, Iwatsubo T, Nakamura Y, Matsuda N, Miyata M, Jin M, Chen T, Kuribayashi K, Tian Y, Hughes R, Yamamoto J, Muralidharan KK, Rubel C, Hutchison RM, Budd Haeberlein S.

J Prev Alzheimers Dis. 2024;11(5):1260-1269. doi: 10.14283/jpad.2024.106.

Insights into the use of biomarkers in clinical trials in Alzheimer's disease

Pascoal TA, Aguzzoli CS, Lussier FZ, Crivelli L, Suemoto CK, Fortea J, Rosa-Neto P, Zimmer ER, Ferreira PCL, Bellaver B.

EBioMedicine. 2024 Oct;108:105322. doi: 10.1016/j.ebiom.2024.105322. Epub 2024 Oct 3.

Challenges in the practical implementation of blood biomarkers for Alzheimer's disease

Schöll M, Verberk IMW, Del Campo M, Delaby C, Therriault J, Chong JR, Palmqvist S, Alcolea D.

Lancet Healthy Longev. 2024 Oct;5(10):100630. doi: 10.1016/j.lanhl.2024.07.013. Epub 2024 Oct 3.

Head-to-head comparison of leading blood tests for Alzheimer's disease pathology

Schindler SE, Petersen KK, Saef B, Tosun D, Shaw LM, Zetterberg H, Dage JL, Ferber K, Triana-Baltzer G, Du-Cuny L, Li Y, Coomaraswamy J, Baratta M, Mordashova Y, Saad ZS, Raunig DL, Ashton NJ, Meyers EA, Rubel CE, Rosenbaugh EG, Bannon AW, Potter WZ; Alzheimer's Disease Neuroimaging Initiative (ADNI) Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium Plasma Aβ and Phosphorylated Tau as Predictors of Amyloid and Tau Positivity in Alzheimer's Disease Project Team.

Alzheimers Dement. 2024 Nov;20(11):8074-8096. doi: 10.1002/alz.14315. Epub 2024 Oct 12.

Survival time in Alzheimer's disease: An overlooked measure of safety and efficacy of disease-modifying therapies

Kurkinen M, Daly T.

Adv Clin Exp Med. 2024 Oct;33(10):1039-1043. doi: 10.17219/acem/194003.

A meta-analysis of bulk RNA-seq datasets identifies potential biomarkers and repurposable therapeutics against Alzheimer's disease

Lamisa AB, Ahammad I, Bhattacharjee A, Hossain MU, Ishtiaque A, Chowdhury ZM, Das KC, Salimullah M, Keya CA.

Sci Rep. 2024 Oct 21;14(1):24717. doi: 10.1038/s41598-024-75431-z.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias